Krebs Biochemicals & Industries Ltd

Krebs Biochemicals & Industries Limited was initially incorporated as 'Krebs Biochemicals Limited' in 1991. The name of the Company was changed from Krebs Biochemicals Limited to Krebs Biochemicals & Industries Limited effected from November 21, 2003. Promoted by R T Ravi, Company engages in manufacture of Active Pharmaceutical Ingredients(API) through Fermentation process, one among very few in the world to do the same. The Company develops commercially viable biotech processes for application in medicine, agriculture and industry. Undertaking contract manufacturing for large pharmaceutical and multinational companies and developing products for sale in global markets, the Company possesses expertise and infrastructure in chemical synthesis, fermentation and enzymatic technologies. KBIL which commenced commercial operations in the year 1994 with an installed capacity of 60 TPA has now grown to 150 TPA. KBL went to public with an IPO in 1994. During 2001-02, the company launched Vitamin C(I P Grade) through Fermentation Process. The Company commissioned 2.5 MW Co-generation Power Plant at Unit II in Vizag during 2003-04 and started operations on it from July, 2004 onwards. Production of two new products has commenced in the Nellore unit of the company during 2008. The sales from Unit II showed a healthy increase and small activity started in Unit I through Contract Manufacturing in 2010-11. The steep drop in income was attributed to discontinuing of Lovastatin manufacturing from April, 2012 in Unit ll. Starting from April 2012, the power supply was restricted the Andhra Pradesh government making it unviable and impractical to run the manufacturing of Lovastatin. Further, this affected the manufacturing of Simvastatin for which Lovastatin as the key raw material. Unit 2 due to the power shortage became sick in 2012. The Company undertook a financial restructuring to revive the operations in 2013. Ipca Laboratories Limited acquired 31.38% stake in the Company, making it an associate Company during FY15. During the year 2015-16, complete repairs and maintenance of both plants were undertaken to make plants ready for operations after the long shutdown. Some modernisation works were undertaken to meet the latest pollution control norms and safety regulations. All relevant licences were renewed. All the pending statutory requirements were addressed. Products range for both plants was established. Scale up operations including technology sourcing/development, pilot plant trials and validation trails for the identified products began in 2016. During the FY 2019-20, A total of four products were produced in its plant including Phenylephrine HCl, Simvastatin, Serratiopeptidase and RSS. The Vizag manufacturing facility of the Company started manufacturing few drug intermediates in 2023. The manufacturing operations at the Company's Vizag manufacturing unit remained closed since 9th February 2025 pursuant to order issued by Andhra Pradesh Pollution Control Board.